Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Qingmo Yang"'
Autor:
Zhiqiang Que, Yilong Lin, Dingqiang Chen, Keyi Xiao, Wenbin Xu, Naikun Sun, Qingmo Yang, Gang Rui
Publikováno v:
Journal of Orthopaedic Surgery and Research, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Osteoporosis and frailty are two common features in the elderly population. Despite many review articles mentioning the association between osteoporosis and frailty, there is a lack of original research directly investigating thei
Externí odkaz:
https://doaj.org/article/3fb7c0c0a5e34e49985740ef5038dc26
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Objective Triple-negative breast cancer (TNBC) represents a particularly aggressive form of breast cancer with a poor prognosis due to a lack of targeted treatments resulting from limited a understanding of the underlying mechanisms. The aim
Externí odkaz:
https://doaj.org/article/a8f77c0cde8b4289b0e070331ec2114c
Autor:
Yilong Lin, Yue Zhang, Songsong Wang, Lin Cao, Ruidan Zhao, Xilai Ma, Qiaolu Yang, Liyi Zhang, Qingmo Yang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe relationship between sodium-glucose cotransporter 2 (SGLT2) inhibitors and prostate cancer is still unknown. Although these inhibitors can influence tumor glycolysis, the underlying mechanism requires further exploration.MethodsA two-sa
Externí odkaz:
https://doaj.org/article/fc1cc124d3c64328b647810b796bc412
Autor:
Qingmo Yang, Xingqiang Zhu, Yulu Liu, Zhi He, Huan Xu, Hailing Zheng, Zhiming Huang, Dan Wang, Xiaofang Lin, Ping Guo, Hongliang Chen
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background Whole-genome methylation sequencing of cfDNA is not cost-effective for tumor detection. Here, we introduce reduced representative methylome profiling (RRMP), which employs restriction enzyme for depletion of AT-rich sequence to ac
Externí odkaz:
https://doaj.org/article/653f2c60340c410096b5bd5377032638
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background The breast-conserving surgery and reconstruction rate in China is relatively low when compared with those in Western countries. Moreover, predictors of surgical choices for women with breast cancer in China have not yet been explo
Externí odkaz:
https://doaj.org/article/1aa9c39e8efd47d9a8dfbf9938a6d183
Autor:
Yusi Zhang MD, Chenyu Sun MD, Vicky Yau MD, Shuanglong Chen MD, Qingmo Yang MD, Wenlin Chen MD, Scott Lowe MD, Rachel Bentley MD, Zhong Ouyang MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
With the improvement of diagnostic techniques, numerous uncommon metastases derived from breast cancer were reported. However, very few studies explored the clinical characteristics and prognostic patterns of these patients. A total of 82 cases of un
Externí odkaz:
https://doaj.org/article/177644c03b464c26aa4f8c3afb49b43e
Publikováno v:
Technology in Cancer Research & Treatment, Vol 21 (2022)
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently. Methods: Between February 2019 to December
Externí odkaz:
https://doaj.org/article/200b6140bdd044e0965fe4a6d3a389c5
Autor:
Minjun Meng, Qiaolu Yang, Zhong Ouyang, Qingmo Yang, Xinyi Wu, Yufan Huang, Yonghui Su, Shuanglong Chen, Wenlin Chen
Publikováno v:
Acta Pharmaceutica. 73:75-90
Breast cancer is one of the most common malignant tumors in women and it is the most frequently diagnosed cancer in the world. Ampelopsin (AMP) is a purified component from the root of Ampelopsis grossedentata. It is reported that AMP could significa
Publikováno v:
BMC cancer. 23(1)
Background The breast-conserving surgery and reconstruction rate in China is relatively low when compared with those in Western countries. Moreover, predictors of surgical choices for women with breast cancer in China have not yet been explored. This
Publikováno v:
Translational Cancer Research
Background Postmastectomy radiation (PMRT) is an important adjuvant treatment for high-risk breast cancer. However, evidence concerning its efficacy in promoting survival of patients with 1–3 positive axillary lymph nodes remains insufficient. Meth